Pharma.Aero and Flanders Vaccine team up for the annual event “Immunity for Health: Innovations in vaccine manufacturing, supply and delivery”
Pharma.Aero and Flanders Vaccine join forces for the upcoming Annual Event ‘Immunity for Health: Innovations in vaccine manufacturing, supply and delivery’. The event is set to take place on 12th of October at Blue Point, Brussels, and promises to be a remarkable platform for discussing critical aspects of the vaccine supply chain.
This year’s programme brings together academic researchers, industry experts and representatives of the logistics sector to discuss bottlenecks and scientific solutions in the vaccine supply chain, upscaling production, cold chain management, cost of goods, innovative delivery systems and other important links in the production and delivery process.
Renowned experts in the field will share their experiences with us during the plenary sessions. Research groups and sme’s will be given the opportunity to share their innovative ideas, technologies or new products with the audience during the pitch sessions.
Detailed program and lineup of speakers here
An interactive panel discussion between scientists, industry and the logistics sector will also be part of the programme. Companies can showcase their technologies and products such as monitoring devices, cold-chain packaging solutions, and much more in the foyer.
Register here
Scientists and young entrepreneurs are invited to pitch their promising project results or innovative technologies related to topics relevant to Immunity for Health 2023.
Flanders Vaccine is a non-profit, strategy-driven platform for academic, industrial and public stakeholders with relevant expertise in human and animal immunotherapeutics and vaccines. Flanders Vaccine brings together universities, public and private hospitals, research centres, SMEs, pharma, competence providers, patient organisations, and government bodies to develop novel immunological health solutions and the vaccines of the future.
Flanders Vaccine supports the development of immunotherapeutics and vaccines for both prophylactic and therapeutic targets in humans and animals by facilitating the exchange of know-how and complementary innovative technologies between academia and industry. The Flanders vaccine platform can be seen as an integrated tool that gives rise to more and better partnerships; that prepares us better for future calls for funding; that enables us to network at inspiring meetings and conferences; that generates visibility and attracts significant attention from national and international experts, stakeholders and organisations.